Study guide

5.5 Privacy, Confidentiality, Documentation & Genomic Data Security

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

5.5 Privacy, Confidentiality, Documentation & Genomic Data Security

Key Takeaways Explain This Topic AI

HIPAA Privacy and Security Rules treat genetic information as protected health information (PHI) when held by covered entities/business associates—governing use, disclosure, and safeguards.

Genetic counseling documentation must be accurate, timely, and sufficient to support clinical care, medical necessity, and continuity—without speculative or judgmental language.

Confidentiality can tension with duties to warn or protect identifiable third parties; genetics cases are taught as counseling/legal-awareness frameworks (Tarasoff-adjacent), not as license to give legal advice.

Genomic data security includes access controls, minimum necessary use, secure transmission/storage, vendor/BA agreements, and caution with email, portals, and research repositories.

Board items reward the best next privacy/documentation/security action—not absolute secrecy promises or casual oversharing with relatives or employers.

Last updated: August 2026

Privacy and security as everyday genetic counseling practice

After GINA’s non-discrimination frame (5.4), Domain 5C turns to how genetic information is handled : who may see it, how it is recorded, when confidentiality yields to competing duties, and how genomic data are secured. The Health Insurance Portability and Accountability Act (HIPAA) Privacy and Security Rules are the federal backbone for covered entities (health plans, most providers, clearinghouses) and their business associates.

On the CGC exam, privacy stems rarely ask you to recite regulatory subsection numbers. They ask whether you recognize PHI , apply minimum necessary thinking, document appropriately, avoid improper disclosures, and respond wisely when a client refuses to tell at-risk relatives.

HIPAA applied to genetic information

Protected health information (PHI) includes individually identifiable health information held or transmitted by a covered entity/business associate. Genetic test results, pedigrees with identifiers, counseling notes, and billing details tied to an individual are classic PHI.

HIPAA concept Practical meaning in genetics Exam cue

Privacy Rule Limits uses/disclosures of PHI; grants patient rights (access, amendments, accounting in defined ways) Can we release results to a relative without authorization?

Security Rule Administrative, physical, and technical safeguards for electronic PHI (ePHI) Portal access, encryption, workstation policies

Minimum necessary Use/disclose only what is needed for the purpose Sending an entire chart when a result summary suffices

Authorization Patient permission for many non-treatment/payment/operations disclosures Employer, life insurer, or curious relative requests

Business associate Vendors handling PHI (labs’ portals, cloud EHR, billing firms) need appropriate agreements/safeguards Who hosts the genomic data?

Genetic information is not “extra-secret HIPAA” by default—but it is sensitive

HIPAA does not create a separate “genetic-only” statute that replaces the Privacy Rule; genetic information is generally handled as PHI with heightened clinical sensitivity. Additional state genetic-privacy laws may impose stricter consent or disclosure rules—acknowledge without inventing statutes (same discipline as GINA state-law teaching).

Treatment, payment, and health-care operations (TPO) disclosures among involved clinicians often proceed under HIPAA without a separate authorization, but “involved” is not unlimited: do not email identifiable results to a relative who is not the patient, post pedigrees to social media, or discuss cases in public spaces.

Documentation standards for genetic counseling

Medical documentation in genetics supports clinical care , continuity , billing/medical necessity , risk management , and patient access rights . High-yield documentation content:

Indication and history — phenotype, family history summary, prior testing.

Counseling provided — risks/benefits/limitations discussed; psychosocial issues; decision aids used.

Informed consent elements for testing (what was ordered, alternatives, residual risk, result types including VUS).

Results disclosure — what was communicated, patient understanding, follow-up plan, cascade recommendations.

Resources and referrals offered.

Privacy/GINA discussion when material to the decision (protections and gaps).

  • Documentation practice Preferred Risky / exam distractor
  • Tone Objective, specific, respectful Pejorative labels (“noncompliant,” “difficult”) without clinical facts
  • Uncertainty Document residual risk and VUS counseling Implying certainty the science does not support
  • Family history Record what was reported and limitations Fabricating relatives to meet testing criteria

Disclosures Note authorizations and what was released “Told sister everything” without patient direction/authority

Amendments Follow institutional process for corrections Quietly altering notes to hide an error

Documentation is discoverable in legal and regulatory processes. Write as if a future clinician—and a future reviewer—must understand the care.

Confidentiality vs duty to warn: genetics awareness (not legal advice)

Genetics uniquely implicates blood relatives . A client may refuse to share a pathogenic variant that would change a sibling’s screening. Classic teaching draws on Tarasoff -adjacent duty-to-warn/protect ideas from mental-health case law and later genetics literature (e.g., discussions around warning identifiable at-risk relatives). For ExamFinch/CGC purposes:

Frame this as counseling and legal-awareness , not as authorizing you to practice law or to declare a universal mandatory warning rule in every jurisdiction.

Typical clinical pathway: explore barriers, offer support for disclosure, provide letters relatives can use, involve supervising clinicians/ethics/legal resources per institution when refusal creates serious preventable harm to identifiable third parties.

Jurisdictions and institutional policies vary . Boards reward process: protect privacy by default, escalate appropriately, document efforts, avoid unilateral gossip to relatives as the first move.

  • Approach When it fits Why
  • Supportive disclosure counseling Most refusal cases Preserves autonomy and often succeeds
  • Written tools for relatives Patient agrees to indirect sharing Maintains accuracy of medical facts
  • Ethics/legal consult High-stakes preventable harm + persistent refusal Policy and law are local

Immediate unauthorized call to a relative Almost never the first board answer Bypasses privacy process and role limits

Emphasize: you are not giving the examinee legal advice to break confidentiality casually . You are teaching recognition of the tension and professional escalation.

Genomic data security basics

Genomic datasets are identifiable or re-identifiable, large, and often shared across labs, EHRs, research repositories, and patient portals. Security literacy for counselors:

Access controls — unique logins, role-based access, no shared passwords.

Secure channels — prefer approved portals/EHR messaging over consumer email for results; if email is used, follow institutional encryption/policy.

Device hygiene — lock screens, avoid PHI on personal devices unless approved.

Minimum necessary downloads — do not export full VCFs to USB “for convenience.”

Vendor awareness — laboratories and software vendors are often business associates; breaches can affect thousands of examinees.

Secondary use caution — research repositories and data-sharing require consent/IRB pathways (see 5.6), not silent clinical reuse.

Breach response — know to report suspected incidents immediately through institutional channels.

  • Risk Example Mitigation
  • Misdirected disclosure Results faxed to wrong clinic Verify identifiers; confirm fax/portal destination

Oversharing in family sessions Discussing one relative’s result with another present without permission Separate encounters; explicit permission

Portal account sharing Spouse uses patient’s login indefinitely Counsel on account control; document authorized representatives properly

  • Unsecured slides Pedigree with names left on conference laptop De-identify teaching cases
  • Integrated scenarios

Scenario A — relative request: A patient’s sister calls asking for the patient’s BRCA result “because we’re family.” Best action: explain you cannot disclose the patient’s PHI without appropriate authorization; offer to help the patient share or provide a release process—not read the result over the phone.

Scenario B — employer letter: Employer requests “all genetic records” after a workplace wellness dispute. Best action: do not release without valid authorization and institutional review; GINA/employment issues may also apply (5.4)—privacy release and non-discrimination are related but distinct.

Scenario C — refusal to inform: Client with a highly penetrant pathogenic variant refuses to tell an identical twin. Best process: explore barriers, offer assistance, document, and involve supervising clinician/ethics/legal resources per policy when serious identifiable harm is at stake—not an immediate unauthorized disclosure as the default first step.

Scenario D — security: Counselor downloads identifiable exome files to a personal laptop to finish a letter at a café on public Wi-Fi. This fails Security Rule/practical security expectations; use approved systems and secure environments.

  • Common traps
  • Disclosing PHI to relatives or employers without authorization because “they deserve to know.”

Promising absolute secrecy that conflicts with mandatory reporting or institutional safety policies.

Charting speculative blame or altering notes improperly.

Treating genomic files as ordinary attachments without safeguards.

Confusing HIPAA privacy with GINA non-discrimination (both may apply; they answer different questions).

Giving definitive legal instructions about Tarasoff duties as if one nationwide genetics rule exists.

Quick exam checklist

Is the requestor the patient or a third party? Authorization needed?

Does documentation support care, consent, and follow-up without harmful language?

If relatives are at risk and the patient refuses, did I counsel, document, and escalate—not freelance disclose?

Are genomic data handled with minimum necessary access and secure systems?

Am I separating privacy (HIPAA), non-discrimination (GINA), and research rules (Common Rule)?